Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. This evidence concerns the gene ABL1 and B-cell acute lymphoblastic leukemia.